<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744236</url>
  </required_header>
  <id_info>
    <org_study_id>DC2012SAFE001</org_study_id>
    <secondary_id>U1111-1130-8248</secondary_id>
    <secondary_id>2012-003256-36</secondary_id>
    <nct_id>NCT01744236</nct_id>
  </id_info>
  <brief_title>SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies</brief_title>
  <official_title>A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Effect of 12-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Liraglutide or Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Sitagliptin on the Cardiovascular, Renal and Gastrointestinal System in Insulin-na√Øve Patients With Type 2 Diabetes (T2DM).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EU FP7: SAFEGUARD consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to detail the (mechanisms underlying the) actions of the GLP-1&#xD;
      receptor agonists and DPP-4 inhibitors on the cardiovascular, renal and gastrointestinal&#xD;
      systems in patients with Type 2 Diabetes Mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GLP-1 receptors are present in most organ systems of the human body, and pharmacological&#xD;
      interventions enhancing GLP-1 activity may influence the function of these organs. The use of&#xD;
      GLP-1 receptor agonists (GLP-1RA) and DPP-4 inhibitors (DPP-4i) has been associated with an&#xD;
      increased heart rate, acute pancreatitis and acute renal failure. To date, studies in humans&#xD;
      detailing the effects of these drugs on these organ systems, biological processes and&#xD;
      underlying mechanisms, which could explain these associations, are lacking.&#xD;
&#xD;
      Therefore, as part of the EU-FP7 SAFEGUARD program, the present study will aim to detail the&#xD;
      (mechanisms underlying the) actions of GLP-1RA and DPP-4i on the cardiovascular, renal and&#xD;
      gastrointestinal system in healthy obese subjects and patients with T2DM.&#xD;
&#xD;
      In the main study, sixty patients with type 2 diabetes will undergo two interventions within&#xD;
      the same protocol in order to assess changes in the outcome parameters:&#xD;
&#xD;
        -  acute study = acute infusion with exenatide or placebo (to assess the cardiovascular and&#xD;
           renal effects)&#xD;
&#xD;
        -  long-term study = 12 weeks of treatment with liraglutide, sitagliptin or placebo (to&#xD;
           assess the cardiovascular, renal and gastrointestinal effects)&#xD;
&#xD;
      In a substudy (termed 'acute MRI study'), twelve patients with type 2 diabetes will undergo&#xD;
      an additional acute intervention study with exenatide (to assess the pancreatic effects)&#xD;
&#xD;
      In a substudy (termed 'pilot-study'), ten healthy obese subjects will undergo a similar acute&#xD;
      study like the patients with type 2 diabetes (to assess the cardiovascular and renal&#xD;
      effects). Moreover, in these healthy subjects, the effects of exenatide during L-NMMA&#xD;
      infusion will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on resting heart rate variability, as derived from electrocardiographic measurements.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on Glomerular Filtration Rate, measured by the inulin-clearance technique.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on pancreatic exocrine function, measured as fecal Elastase-1.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following cardiovascular parameters:</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood pressure and heart rate&#xD;
Hemodynamic variables (blood pressure, heart rate, stroke volume, cardiac output/-index/-contractility, systemic vascular resistance) derived from non-invasive beat-to-beat finger blood pressure measurements&#xD;
Cardiac autonomic nervous system function&#xD;
Microvascular function and vasomotion&#xD;
Arterial stiffness&#xD;
Lipid spectrum&#xD;
Glycemic variables (HbA1c, fasting and postprandial glucose)&#xD;
Body anthropometrics: body weight, height, BMI and waist circumference&#xD;
Body fat content</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following renal parameters:</measure>
    <time_frame>12 weeks</time_frame>
    <description>Effective renal plasma flow (ERPF)&#xD;
Renal tubular function&#xD;
Renal damage, measured by urine biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline following infusion of GLP-1RA (acute effects*) and changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following gastrointestinal parameters:</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pancreatic exocrine function (* In the acute intervention only exocrine pancreatic function is assessed)&#xD;
Pancreatic structure&#xD;
Pancreatic enzymes&#xD;
Gallbladder emptying speed&#xD;
Liver enzymes&#xD;
Hepatic structure/steatosis&#xD;
Gastric emptying</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Liraglutide (main study, long-term intervention)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm (n=20) will receive liraglutide 1.8mg and sitagliptin-placebo during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin (main study, long-term intervention)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm (n=20) will receive sitagliptin 100mg and liraglutide-placebo during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (main study, long-term intervention)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm (n=20) will receive liraglutide-placebo and sitagliptin-placebo during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide (main study, acute intervention)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prior to the 12-week intervention study, a GLP-1 receptor agonist (exenatide) will be administered intravenously (n=30).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (main study, acute intervention)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prior to the 12-week intervention study, placebo will be administered intravenously (n=30).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute MRI intervention study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In a subset of 12 patients with type 2 diabetes, a crossover trial with acute infusion of exenatide and placebo is performed. This is done prior to the 12-week intervention study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilot-study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In 10 healthy obese subjects, a crossover trial with acute infusion of exenatide, placebo and L-NMMA is performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.</description>
    <arm_group_label>Liraglutide (main study, long-term intervention)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin 100mg will be given once daily for 12 weeks.</description>
    <arm_group_label>Sitagliptin (main study, long-term intervention)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests</description>
    <arm_group_label>Acute MRI intervention study</arm_group_label>
    <arm_group_label>Exenatide (main study, acute intervention)</arm_group_label>
    <arm_group_label>Pilot-study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide placebo</intervention_name>
    <description>Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.</description>
    <arm_group_label>Placebo (main study, long-term intervention)</arm_group_label>
    <arm_group_label>Sitagliptin (main study, long-term intervention)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin placebo</intervention_name>
    <description>Sitagliptin-placebo be given once daily for 12 weeks.</description>
    <arm_group_label>Liraglutide (main study, long-term intervention)</arm_group_label>
    <arm_group_label>Placebo (main study, long-term intervention)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide placebo</intervention_name>
    <description>Exenatide-placebo (saline) will be administered intravenously</description>
    <arm_group_label>Acute MRI intervention study</arm_group_label>
    <arm_group_label>Pilot-study</arm_group_label>
    <arm_group_label>Placebo (main study, acute intervention)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-NMMA</intervention_name>
    <arm_group_label>Pilot-study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 35 and 75 years.&#xD;
&#xD;
          -  Females must be post-menopausal (no menses &gt;1 year).&#xD;
&#xD;
          -  Type 2 diabetes (HbA1c 6.5-9% DCCT or 48-75 mmol/mol IFCC), who are being treated with&#xD;
             a stable dose of oral antihyperglycemic agents (either metformin alone, SU alone or a&#xD;
             combination of metformin and SU) for at least 3 months prior to inclusion.&#xD;
&#xD;
          -  BMI 25 - 40 kg/m2&#xD;
&#xD;
          -  Caucasian&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  GFR &lt; 60 mL/min/1.73m2&#xD;
&#xD;
          -  Current / chronic use of the following medication: thiazolidinediones, GLP-1RA,&#xD;
             DPP-4i, glucocorticoids, NSAIDs, insulin, antimicrobial agents, chemotherapeutics or&#xD;
             immune suppressants. Subjects on diuretics will only be excluded when these drugs&#xD;
             (e.g. hydrochlorothiazide) cannot be stopped for the duration of the study.&#xD;
&#xD;
          -  History of or actual pancreatic disease or impaired pancreatic exocrine function&#xD;
&#xD;
          -  Active liver disease&#xD;
&#xD;
          -  History of or actual malignancy (with the exception of basal cell carcinoma)&#xD;
&#xD;
          -  Current urinary tract infection and active nephritis&#xD;
&#xD;
          -  Recent (&lt;6 months) history of cardiovascular disease, including acute coronary&#xD;
             syndrome, stroke, transient ischemic neurologic disorder or chronic heart failure (New&#xD;
             York Heart Association grade II-IV)&#xD;
&#xD;
          -  Current atrial fibrillation&#xD;
&#xD;
          -  Chronic infectious or auto-immune disease&#xD;
&#xD;
          -  Substance and/or alcohol abuse&#xD;
&#xD;
          -  History of allergy/hypersensitivity to any of the test agents&#xD;
&#xD;
          -  Complaints compatible with or established gastroparesis and/or neurogenic bladder&#xD;
&#xD;
          -  Any condition that has been recognized as a contra-indication for the use of GLP-1RA&#xD;
             and DPP-4i, as listed in the respective SPCs&#xD;
&#xD;
          -  History of or actual (severe) mental illness&#xD;
&#xD;
          -  Inability to understand the study protocol and/or inability to give informed consent&#xD;
&#xD;
          -  History of claustrophobia or presence of metal objects/implants (because of MRI&#xD;
             protocol)&#xD;
&#xD;
        For the preceding Pilot study, we will include:&#xD;
&#xD;
          -  Males&#xD;
&#xD;
          -  Age between 18 and 50 years&#xD;
&#xD;
          -  BMI 25 - 40 kg/m2&#xD;
&#xD;
          -  Caucasian&#xD;
&#xD;
        The exclusion criteria for the preceding pilot study are similar to the exclusion criteria&#xD;
        of the main study, with the additions of:&#xD;
&#xD;
          -  Subjects with a fasting plasma glucose ‚â•5.6 mmol/L, a 2-hour glucose of ‚â•7.8 mmol/L&#xD;
             after a 75-grams oral glucose tolerance test, or a HbA1c of ‚â•6.5%&#xD;
&#xD;
          -  Subjects using any kind of medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M.H.H. Kramer, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.safeguard-diabetes.org/</url>
    <description>The website of the European project SAFEGUARD</description>
  </link>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>M.H.H. Kramer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>GLP-1 Receptor Agonists, DPP-4 inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

